ArticleScientific reports2019
A calculator based on prostate imaging reporting and data system version 2 (PI-RADS V2) is a promising prostate cancer predictor.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Coping with Complications that Occur after Prostate Biopsy for Satisfactory Evaluation of Call Service Using Artificial Intelligence: A Pilot Randomized Controlled Trial.The world journal of men's health · 2025Article
- Comparative analysis of ultrasound-guided magnetic resonance imaging-cognitive fusion transrectal versus transperineal prostate biopsy: a 10-year single-center retrospective analysis.Frontiers in medicine · 2025Article
- Development and validation of a nomogram based on biparametric MRI PI-RADS v2.1 and clinical parameters to avoid unnecessary prostate biopsies.BMC medical imaging · 2023Article
- Use of artificial intelligence in discerning the need for prostate biopsy and readiness for clinical practice: a systematic review protocol.Systematic reviews · 2023Article
- Lncap-AI prostate cancer cell line establishment by Flutamide and androgen-free environment to promote cell adherent.BMC molecular and cell biology · 2022Article
- Combining prostate-specific antigen density with prostate imaging reporting and data system score version 2.1 to improve detection of clinically significant prostate cancer: A retrospective study.Frontiers in oncology · 2022Article
- Evaluation of the Predictive Role of Blood-Based Biomarkers in the Context of Suspicious Prostate MRI in Patients Undergoing Prostate Biopsy.Journal of personalized medicine · 2021Article
- Early Diagnosis of Prostate Cancer from the Perspective of Chinese Physicians.Journal of Cancer · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This research is to develop a new tool to improve the performance of predicting prostate cancer (PCa) and reducing unnecessary biopsies. The clinical data of patients who were definitely diagnosed by prostate biopsy were retrospectively analyzed. PCa risks that include age, prostate-specific antigen (PSA), PSA density (PSAD), free-PSA (fPSA), the ratio of fPSA to PSA (%fPSA), prostate volume (PV), digital rectal examination (DRE) and multi-parametric magnetic resonance imaging (MP-MRI) were selected by univariate and multivariate analysis. The satisfactory risks were used to establish predictor (Prostate Biopsy Rating Scale, PBRS). The total score (TS) that was obtained from PBRS was performed to forecast PCa. The areas under the receiver operating characteristic curve (AUC) and the net reclassification index (NRI) were used to compare the predictive ability. A total of 1078 cases were recruited. The mean values of TS in PCa and non-PCa were 15.94 ± 3.26 and 10.49 ± 3.36 points respectively. The AUC of PBRS was higher than PSA, PSAD and MP-MRI (0.87 vs. 0.75, 0.78, 0.80, respectively). PBRS can reduce unnecessary biopsies compared with PSA, PSAD and MP-MRI by up to 63%, 54% and 44%, respectively. In brief, PBRS is a promising predictor of forecasting PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.